In the field of neurology, there have been an increasing number of large-scale clinical trials for neurological diseases. To conduct large-scale clinical trials for neurological diseases, there are issues to be worked out. We need good infrastructures including multicenter-based consortia. We need better measures to evaluate the efficacy of the treatment, which are particularly important for the clinical trial of “disease-modifying therapy”. Since neurodegenerative diseases are slowly progressive diseases, we may need a long duration for assessing the clinical efficacy. We need sensitive measures including surrogate markers. This symposium will focus on recent achievements of clinical trials for neurological diseases, discussing on issues and future directions of large-scale clinical trials.